Tesofensine
Monograph · CTesofensine
Triple monoamine reuptake inhibitor (NE/DA/5-HT). Not a peptide — small molecule. Reduces appetite via central monoaminergic pathways.
How it clearsHalf cleared in ~8d. Most (~96%) gone by ~42d.
Compare these compounds
Mechanism, evidence, legal path, cost — all side-by-side.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
Originally a NeuroSearch Alzheimer/Parkinson candidate. Phase 2 obesity trial (Astrup 2008) showed strong weight loss but blood-pressure and tachycardia signals. Currently approved in Mexico as Tesomet (with metoprolol). Not FDA-approved.
Emerging metabolic evidence with a real mechanistic basis — but the dose-response curve is wider than in established compounds. The first 3–4 weeks should be treated as response-threshold discovery, not outcome measurement. Individual variation here is a feature of the tier, not a flaw in the compound.
Not a peptide; included for stack context. Cardiovascular safety signals from Phase 2 are real. Mexican Tesomet approval is contingent on combined metoprolol — solo tesofensine carries higher BP/HR risk.
Upload your data to see how it relates to Tesofensine.
Upload a lab file (LabCorp / Quest) or DNA file (23andMe / AncestryDNA). Stack will show your specific markers alongside the literature-reported response windows.
Upload in /historyPer-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- CLimited evidence
Triple monoamine reuptake inhibitor (NE/DA/5-HT)
1 supporting referencesVerified 23d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
No field reports yet
Field reports are added as users share their real-world protocols.
Next visit & citations
Handoff & sources
Running this compound? Log it in /history, then open Dr Passport before your visit. Methodology explains grades; the research dashboard sorts the full catalog with citations.